[go: up one dir, main page]

MA56607A1 - Méthodes de traitement de troubles dépressifs - Google Patents

Méthodes de traitement de troubles dépressifs

Info

Publication number
MA56607A1
MA56607A1 MA56607A MA56607A MA56607A1 MA 56607 A1 MA56607 A1 MA 56607A1 MA 56607 A MA56607 A MA 56607A MA 56607 A MA56607 A MA 56607A MA 56607 A1 MA56607 A1 MA 56607A1
Authority
MA
Morocco
Prior art keywords
methods
depressive disorders
treating depressive
compound
present
Prior art date
Application number
MA56607A
Other languages
English (en)
Inventor
Gregory N Beatch
Cynthia Louise Harden
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA56607A1 publication Critical patent/MA56607A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Selon certains modes de réalisation, la présente invention concerne des méthodes et des utilisations pour traiter des troubles dépressifs chez un être humain, les méthodes comprenant l'administration par voie orale d'une quantité thérapeutiquement efficace de n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-diméthylphényl]-3,3-diméthylbutanamide (composé a), à la personne nécessitant un tel traitement. La présente invention concerne également diverses méthodes améliorées de thérapie et d'administration du composé a.
MA56607A 2019-11-08 2020-11-06 Méthodes de traitement de troubles dépressifs MA56607A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932724P 2019-11-08 2019-11-08
PCT/US2020/059481 WO2021092439A1 (fr) 2019-11-08 2020-11-06 Méthodes de traitement de troubles dépressifs

Publications (1)

Publication Number Publication Date
MA56607A1 true MA56607A1 (fr) 2022-10-31

Family

ID=73643360

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56607A MA56607A1 (fr) 2019-11-08 2020-11-06 Méthodes de traitement de troubles dépressifs

Country Status (20)

Country Link
US (2) US12178811B2 (fr)
EP (1) EP4054580A1 (fr)
JP (2) JP2022553569A (fr)
KR (1) KR20220098746A (fr)
CN (1) CN114667146A (fr)
AU (1) AU2020380961A1 (fr)
BR (1) BR112022008580A2 (fr)
CA (1) CA3155812A1 (fr)
CL (1) CL2022001102A1 (fr)
CO (1) CO2022008001A2 (fr)
CR (1) CR20220250A (fr)
GE (2) GEP20257732B (fr)
IL (1) IL292678A (fr)
MA (1) MA56607A1 (fr)
MX (1) MX2022005490A (fr)
NZ (1) NZ787838A (fr)
PE (1) PE20221766A1 (fr)
PH (1) PH12022551110A1 (fr)
TW (1) TW202128162A (fr)
WO (1) WO2021092439A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
EP4291189A1 (fr) * 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonie
CN117015379A (zh) * 2021-02-09 2023-11-07 泽农医药公司 用于治疗癫痫发作病症的联合疗法

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639385A (en) 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
EP0110091B1 (fr) 1982-10-27 1987-01-21 Degussa Aktiengesellschaft Dérivés de la 2-amino-3-acylamino-6-benzylamino-pyridine à activité antiépileptique
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
EP0189788B1 (fr) 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Combinaison synergétique de flupirtine et d'anti-phlogistiques non-stéroidaux
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
EP0193056B1 (fr) 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Combinaison de la flupirtine avec des spasmolytiques à effet anticholinergique
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (fr) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (fr) 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
DE69434794T2 (de) 1994-09-22 2007-07-12 Smith, Richard Alan, La Jolla Kombination von dextromethorphan mit quinidine oder quinine sulfat zur behandlung verschiedener refraktärer störungen
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
CN1160115C (zh) 1994-12-12 2004-08-04 奥默罗斯公司 用于抑制疼痛,炎症和痉挛的冲洗液和方法
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU8561298A (en) 1997-08-08 1999-03-01 Chugai Seiyaku Kabushiki Kaisha Remedies for complications of diabetes
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
AU764921B2 (en) 1998-12-14 2003-09-04 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
AU3216600A (en) 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1163225A1 (fr) 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Composes et techniques de modulation des recepteurs des oestrogenes
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
CZ20014488A3 (cs) 1999-07-06 2003-01-15 Eli Lilly And Company Selektivní antagonisté iGluR5 receptoru pro léčení migrény
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
CA2378241A1 (fr) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides comme ouvreurs de canaux potassiques
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
WO2002080898A2 (fr) 2001-04-04 2002-10-17 Wyeth Methodes de traitement de la motilite gastrique hyperactive
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (fr) 2002-02-12 2003-08-21 Pfizer Inc. Composes non-peptidiques influant sur l'action de la gnrh
US6984647B2 (en) 2002-05-17 2006-01-10 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid VR1 receptor
WO2003106454A1 (fr) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd Derives de 1h-isoquinoline-oxazolidinone, et leur utilisation comme agents antibacteriens
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7045551B2 (en) 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
WO2004058704A2 (fr) 2002-12-23 2004-07-15 Icagen, Inc. Quinazolinones comme modulateurs de canaux potassiques
MXPA05006463A (es) 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
WO2004080950A1 (fr) 2003-03-14 2004-09-23 H. Lundbeck A/S Derives d'aniline substitues
MXPA05010000A (es) 2003-03-21 2005-11-17 Lundbeck & Co As H Derivados de p-diaminobenceno substituidos.
WO2004096767A1 (fr) 2003-04-25 2004-11-11 H. Lundbeck A/S Derives indole et indoline substitues
RS20050868A (sr) 2003-05-27 2007-08-03 Altana Pharma Ag., Farmaceutske kombinacije inhibotora protonske pumpe i jedinjenje koje modifikuje gastrointestinalni motilitet
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
EP1663239A4 (fr) 2003-09-10 2008-07-23 Cedars Sinai Medical Center Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
CA2560346A1 (fr) 2004-04-13 2005-10-27 Icagen, Inc. Pyridines polycycliques en tant que modulateurs de canal ionique du potassium
RU2006139930A (ru) 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
WO2006054513A1 (fr) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Agent préventif ou thérapeutique pour la douleur neuropathique
EP1688141A1 (fr) 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
EP2298766B1 (fr) 2005-03-03 2013-09-18 H. Lundbeck A/S Formulations pharmaceutiques comprenant un dérivé de pyridine substitué
EP1891089B1 (fr) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. Inhibiteurs de protease du VHC en combinaison avec des aliments
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
WO2007128462A1 (fr) 2006-05-02 2007-11-15 Chris Rundfeldt Activateurs de canaux potassiques pour la prévention et le traitement de la dystonie et des systèmes assimilés à la dystonie
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
ES2375417T3 (es) 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
WO2008144320A2 (fr) 2007-05-17 2008-11-27 Endo Pharmaceuticals, Inc. Opioïde et procédés de fabrication et d'utilisation de celui-ci
UA97847C2 (ru) * 2007-08-01 2012-03-26 Х. Луннбек А/С Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии
US20110003867A1 (en) * 2007-12-11 2011-01-06 Neurosearch A/S Novel 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators
US20100323016A1 (en) 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
JP2013517315A (ja) 2010-01-20 2013-05-16 グラクソ グループ リミテッド 新規組成物
WO2013067591A1 (fr) 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Formulations topiques pour gestion de la douleur
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
HRP20230808T1 (hr) * 2018-02-20 2023-11-10 H. Lundbeck A/S Derivati alkohola kao otvarači kv7 kalijevih kanala
BR112020022713A2 (pt) 2018-05-11 2021-02-02 Xenon Pharmaceuticals Inc. métodos para aumentar a biodisponibilidade e exposição de uma abertura de canal de potássio dependente de voltagem
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
WO2021113802A1 (fr) 2019-12-06 2021-06-10 Icahn School Of Medicine At Mount Sinai Procédé de traitement avec des activateurs de canaux kcnq
US20210213009A1 (en) 2019-12-13 2021-07-15 Xenon Pharmaceuticals Inc. Methods of treating pain
EP4291189A1 (fr) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonie
CN117015379A (zh) 2021-02-09 2023-11-07 泽农医药公司 用于治疗癫痫发作病症的联合疗法
IL291332B2 (en) 2021-10-27 2025-10-01 Shanghai Zhimeng Biopharma Inc Potassium channel blocker, method of preparation and uses

Also Published As

Publication number Publication date
BR112022008580A2 (pt) 2022-08-09
NZ787838A (en) 2025-08-29
JP2022553569A (ja) 2022-12-23
PH12022551110A1 (en) 2024-02-26
CL2022001102A1 (es) 2023-01-27
EP4054580A1 (fr) 2022-09-14
WO2021092439A1 (fr) 2021-05-14
CN114667146A (zh) 2022-06-24
JP2026001049A (ja) 2026-01-06
GEAP202415942A (en) 2024-10-28
CO2022008001A2 (es) 2022-06-10
TW202128162A (zh) 2021-08-01
KR20220098746A (ko) 2022-07-12
PE20221766A1 (es) 2022-11-11
US20210161886A1 (en) 2021-06-03
US12178811B2 (en) 2024-12-31
CR20220250A (es) 2022-08-19
AU2020380961A1 (en) 2022-05-26
IL292678A (en) 2022-07-01
GEP20257732B (en) 2025-02-10
CA3155812A1 (fr) 2021-05-14
MX2022005490A (es) 2022-08-10
US20250108044A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MA56607A1 (fr) Méthodes de traitement de troubles dépressifs
MA52569B1 (fr) Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant
MA51627B1 (fr) Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
DE60125541D1 (de) Neue nicht psychotropische cannabinoide
EA199900669A1 (ru) Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
BG98827A (bg) Фармацевтичен състав и метод за неговото получаване
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
WO2001091796A8 (fr) Methodes, composes et compositions permettant de traiter la goutte
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
MA62148B1 (fr) Inhibiteur de magl
DE69827295D1 (de) Kombination von einem den retinoinsäure metabolismus blockierenden arzneimittel und einem tocopherol
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
EA200400302A1 (ru) Способ лечения первичной бессонницы
DE69512940D1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
DE69924979D1 (de) Behandlung von chronischen schmerzen
NO20052999L (no) Ny synergistisk kombinasjon omfattende roflumilast og formoterol
MA61730A1 (fr) Thérapie conjointe pour le traitement de crises épileptiques
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
MA56958A1 (fr) Utilisation d'un agent d'ouverture du canal potassique kv7 pour le traitement de la douleur